KOOL - Cesca Therapeutics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.64
+0.01 (+0.38%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close2.63
Open2.66
Bid2.60 x 300
Ask4.46 x 200
Day's Range2.63 - 2.68
52 Week Range2.41 - 6.44
Volume17,825
Avg. Volume130,536
Market Cap28.684M
Beta0.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Financially Strong Is Cesca Therapeutics Inc (KOOL)?
    Simply Wall St.9 days ago

    How Financially Strong Is Cesca Therapeutics Inc (KOOL)?

    Cesca Therapeutics Inc (NASDAQ:KOOL) is a small-cap stock with a market capitalization of $29.99M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • Capital Cube15 days ago

    ETFs with exposure to Cesca Therapeutics, Inc. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cesca Therapeutics, Inc. Here are 5 ETFs with the largest exposure to KOOL-US. Comparing the performance and risk of Cesca Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • American City Business Journals17 days ago

    Cesca Therapeutics aims to raise nearly $3 million with share offering

    Cesca Therapeutics Inc., a Rancho Cordova-based developer of regenerative medicine technology, announced a public share offering that aims to raise $2.7 million through the sale of 900,000 shares at $3 per share. The gross proceeds from the offering are expected to be $2.7 million, with $2.3 million going to Cesca (KOOL) after the placement agent’s commission and other expenses. Dawson James Securities Inc. is serving as the placement agent for the offering.

  • Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017
    Capital Cube2 months ago

    Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Cesca Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Cesca Therapeutics, Inc. – Kewaunee Scientific Corporation (KEQU-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 3.50 million, Net Earnings of USD -1.15 ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Cesca Therapeutics, Inc. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cesca Therapeutics, Inc. Here are 5 ETFs with the largest exposure to KOOL-US. Comparing the performance and risk of Cesca Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: 2017 By the Numbers : September 25, 2017
    Capital Cube3 months ago

    Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: 2017 By the Numbers : September 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Cesca Therapeutics, Inc. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of Cesca Therapeutics, Inc. – Kewaunee Scientific Corporation, Cerus Corporation, Stryker Corporation, Haemonetics Corporation and Cytori Therapeutics, Inc. (KEQU-US, CERS-US, SYK-US, HAE-US and CYTX-US) that have also reported for ... Read more (Read more...)

  • GuruFocus.com3 months ago

    Cesca Therapeutics Inc (KOOL) Files 10-K for the Fiscal Year Ended on June 30, 2017

    Cesca Therapeutics Inc (NASDAQ:KOOL) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017.

  • TheStreet.com5 months ago

    Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

    And a management shakeup helps push down NuVasive.

  • Zacks5 months ago

    Company News for July 11, 2017

    Companies in the News are: HCOM,CBB,KOOL,MYCC,APO,CETV

  • Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
    Capital Cube7 months ago

    Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Cesca Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Cesca Therapeutics, Inc. – Haemonetics Corporation, Cerus Corporation, Stryker Corporation, Cytori Therapeutics, Inc. and Span-America Medical Systems, Inc. (HAE-US, CERS-US, SYK-US, CYTX-US and SPAN-US) that have also reported ... Read more (Read more...)

  • Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017
    Capital Cube9 months ago

    Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Cesca Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Cesca Therapeutics, Inc. – Kewaunee Scientific Corporation, Haemonetics Corporation, Cerus Corporation, Stryker Corporation and Span-America Medical Systems, Inc. (KEQU-US, HAE-US, CERS-US, SYK-US and SPAN-US) that have also reported ... Read more (Read more...)

  • 24/7 Wall St.9 months ago

    Wednesday’s Biggest Biopharma Movers

    The broad markets are inching forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) is up about 1% on the day, there are ...

  • 24/7 Wall St.11 months ago

    Insiders Keep Buying as Market Wraps on 2016: Tronic, Six Flags, Virtu Financial, Cesca Therapeutics and More

    Despite all three of the major indexes closing at one point at all-time highs for the first time since 1999, the insider buying was full speed ahead almost all year.

  • Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major Movers
    Insider Monkeylast year

    Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major Movers

    The second-to-last trading day of 2016 is showing little volatility in the broader market, with the S&P, Dow, and Nasdaq all being close to flat (the Nasdaq is faring the worst, as it’s shed 0.15% of its value). Among the data points that investors are mulling over today are the recent jobless claims report, as […]